Capcitab 150 mg (Capecitabine) Tablets

Capcitab 150 mg (Capecitabine) Tablets – Precision Oral Chemotherapy Solution

Overview

Capcitab 150 mg contains Capecitabine, an innovative oral chemotherapy medication that transforms cancer treatment by offering patients a convenient and effective alternative to traditional intravenous chemotherapy. This lower-dose formulation provides oncologists with greater flexibility in treatment protocols, enabling more precise dosing adjustments based on patient needs. Distributed globally by Saif Pharma, Capcitab 150 mg represents an important advancement in accessible cancer care, bringing hospital-grade treatment into patients’ homes.

Mechanism of Action

Capecitabine functions as a sophisticated prodrug that undergoes a three-step enzymatic conversion process to become the active anticancer compound 5-fluorouracil (5-FU) directly within tumor tissues. This targeted conversion process occurs through:

1. Initial absorption through the gastrointestinal tract after oral administration
2. Preliminary processing in the liver by carboxylesterase
3. Final conversion to active 5-FU preferentially within tumor cells due to higher concentrations of thymidine phosphorylase

The active 5-FU then disrupts cancer cell growth and replication through two complementary mechanisms:

• Thymidylate Synthase Inhibition: The metabolite FdUMP (5-fluoro-2′-deoxyuridine monophosphate) forms a stable complex with thymidylate synthase and folate cofactor (N5-10-methylene tetrahydrofolate). This interaction blocks the production of thymidylate, a critical precursor of thymidine triphosphate necessary for DNA synthesis, effectively halting cell division.
• RNA Function Disruption: The metabolite FUTP (5-fluorouridine triphosphate) is incorporated into RNA in place of uridine triphosphate (UTP), interfering with RNA processing and function, which compromises protein synthesis and cellular metabolism in cancer cells.

This dual mechanism makes Capcitab particularly effective against rapidly proliferating tumor cells while offering the significant advantage of targeted activation primarily within tumor tissues.

Clinical Applications

Capcitab 150 mg is indicated for the treatment of several cancer types, including:

• Metastatic breast cancer (particularly in combination with docetaxel)
• Colorectal cancer (both as adjuvant therapy and for metastatic disease)
• Advanced gastric cancer
• Pancreatic cancer (as combination therapy)

The 150 mg tablet strength provides oncologists with dosing flexibility for:

• Patients requiring lower doses due to body surface area calculations
• Individuals needing dose modifications due to side effects
• Customized treatment regimens based on specific cancer protocols
• Gradual dose escalation strategies

Dosage & Administration

Capcitab 150 mg tablets are designed for oral administration, typically given twice daily (morning and evening) within 30 minutes after meals. The specific dosing schedule is determined by healthcare providers based on individual factors including:

• Body surface area
• Specific cancer type and stage
• Overall health status and organ function
• Prior treatment history
• Concomitant medications

Treatment is usually administered in cycles with rest periods between active treatment phases. The 150 mg tablet strength can be combined with 500 mg tablets for precise dosing according to your oncologist’s prescription.

Product Quality Assurance

Capcitab 150 mg is manufactured under stringent quality control protocols to ensure consistent potency, stability, and efficacy. Every batch undergoes comprehensive testing to verify:

• Precise active ingredient content
• Dissolution profile meeting pharmaceutical standards
• Freedom from contaminants
• Stability throughout the labeled shelf life

As distributed by Saif Pharma, this medication adheres to international quality standards for oncology pharmaceuticals.

Global Availability

Through Saif Pharma’s extensive distribution network spanning over 60 countries, Capcitab 150 mg reaches patients worldwide, including major markets such as:

• United States
• Canada
• Saudi Arabia
• United Arab Emirates
• China
• India
• Pakistan

This global reach ensures that patients across diverse geographic regions can access this important treatment option without disruption.

Advantages of Capcitab 150 mg

1. Dosing Flexibility: The 150 mg strength allows for more precise dose adjustments than larger tablet sizes alone
2. Oral Administration: Eliminates the need for frequent hospital visits for IV chemotherapy
3. Tumor-Targeted Activation: Preferential conversion to active form within tumor tissues helps minimize systemic toxicity
4. Proven Efficacy: Backed by extensive clinical research demonstrating effectiveness across multiple cancer types
5. Treatment Versatility: Effective both as monotherapy and in combination with other anticancer agents
6. Cost-Effectiveness: Offered at competitive pricing to improve accessibility for patients globally
7. Convenient Administration: Simple oral dosing that patients can manage at home with proper guidance

About Saif Pharma

Established in 2014, Saif Pharma has quickly emerged as a leading global supplier, trader, and distributor specializing in oncology medicines. With operations extending to more than 60 countries, the company has built a sterling reputation for providing high-quality, affordable cancer treatments worldwide.

Saif Pharma’s core mission centers on increasing accessibility to essential oncology medications, focusing particularly on:

• Maintaining reliable supply chains for critical cancer treatments
• Ensuring competitive pricing to reduce financial burdens on patients
• Upholding rigorous quality standards across all distributed products
• Expanding availability of advanced treatments to underserved regions

This commitment to quality and accessibility has earned Saif Pharma a prestigious position in the global pharmaceutical market, particularly in oncology care.

Comprehensive Cancer Care Approach

Cancer treatment requires not only effective medications but also consistent access to these treatments throughout the course of therapy. Capcitab 150 mg, as distributed by Saif Pharma, represents an important component in the comprehensive approach to cancer care, providing:

• Flexible dosing options for personalized treatment plans
• Consistent quality that physicians and patients can trust
• Global availability that helps ensure uninterrupted treatment
• Affordability that addresses the financial aspects of cancer care

For more information about Capcitab 150 mg (Capecitabine) or to inquire about availability in your region, please visit www.saifpharma.com or consult with your healthcare provider.